KENILWORTH, N.J.–(BUSINESS WIRE) October 15, 2020 — Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced
Continue reading »Home »
Pembrolizumab use supported in advanced melanoma
(HealthDay)—Use of pembrolizumab is supported among patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior receipt of
Continue reading »